Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sean Tunis

Baltimore, MD Medical Doctor

CMS profile 1314467

4712 Keswick Rd, Baltimore, MD 21210

Open in the dashboard

General payments

$361,450

129 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sean Tunis of Baltimore, MD is reported in the CMS Open Payments database as having received $361,450 across 129 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $42,439 10
2024 General $31,611 27
2023 General $102,325 33
2022 General $35,762 10
2021 General $34,398 7
2020 General $50,897 13
2019 General $64,019 29

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sean Tunis
  • Maryland median
  • Middle half of Maryland
  • National median

In program year 2025, general payments to Sean Tunis were reported at $42,439. Among 20,588 Maryland profiles paid that year, the median was $166 and the middle half received between $51 and $580.

Show as a table
Year Sean Tunis Maryland median Middle half National median
2019 $64,019 $165 $50–$633 $163
2020 $50,897 $114 $37–$407 $114
2021 $34,398 $130 $36–$480 $132
2022 $35,762 $150 $45–$529 $149
2023 $102,325 $155 $47–$557 $160
2024 $31,611 $169 $53–$600 $164
2025 $42,439 $166 $51–$580 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Merck Sharp & Dohme Corporation $67,142 20 payments
  2. AveXis $67,058 36 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $37,489 22 payments
  4. Edwards Lifesciences Corporation $34,449 25 payments
  5. Ucb SA $27,654 1 payment
  6. Janssen Scientific Affairs, LLC $27,300 3 payments
  7. AstraZeneca UK Limited $27,000 5 payments
  8. Otsuka America Pharmaceutical, Inc. $21,350 5 payments
  9. Amgen Inc. $15,058 7 payments
  10. Allergan Inc. $11,200 1 payment
  11. Other $25,750 4 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $270,814 57 payments
  2. Honoraria $38,367 6 payments
  3. Travel and Lodging $34,973 34 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $12,984 12 payments
  5. Education $3,065 4 payments
  6. Food and Beverage $1,246 16 payments
Products named General payments · program years 2019–2025
  1. INVEGA SUSTENNA $27,300 3 payments
  2. ZOLGENSMA $25,984 20 payments
  3. JARDIANCE Diabetes $25,789 15 payments
  4. JARDIANCE Diabetes $11,700 7 payments
  5. REXULTI $9,000 1 payment
  6. TAGRISSO $6,750 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

129 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record